Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom

Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System

(2015) Nikolai Madrid Scheller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vaccines, adjuvants and autoimmunity

(2015) Luísa Eça Guimarães et al.   PHARMACOLOGICAL RESEARCH

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

(2014) S Rachel Skinner et al.   LANCET

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

(2014) Maria-Genalin Angelo et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

(2014) Maria-Genalin Angelo et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

(2014) Paulo S Naud et al.   Human Vaccines & Immunotherapeutics

Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects

(2013) L. Grimaldi-Bensouda et al.   JOURNAL OF INTERNAL MEDICINE

Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines

(2013) Fernanda Tavares Da Silva et al.   VACCINE

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

(2013) L. Arnheim-Dahlstrom et al.   BMJ-British Medical Journal

Validation of suicide and self-harm records in the Clinical Practice Research Datalink

(2012) Kyla H. Thomas et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women

(2012) Steven J. Jacobsen et al.   VACCINE

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

(2011) C. Chao et al.   JOURNAL OF INTERNAL MEDICINE

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink

(2011) Julianne Gee et al.   VACCINE

Pathology and epidemiology of HPV infection in females

(2010) Margaret Stanley   GYNECOLOGIC ONCOLOGY

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

(2010) Dominique Descamps et al.   Human vaccines & immunotherapeutics

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine

(2009) Barbara A. Slade   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies

(2009) Nicola P. Klein et al.   VACCINE